Abstract:Sphingolipids, sphingolipid metabolizing enzymes, and their receptors network are being recognized as part of the signaling mechanisms, which govern breast cancer cell growth, migration, and survival during chemotherapy treatment. Approximately 70% of breast cancers are estrogen receptor (ER) positive and, thus, rely on estrogen signaling. Estrogen activates an intracellular network composed of many cytoplasmic and nuclear mediators. Some estrogen effects can be mediated by sphingolipids. Estrogen activates sphingosine kinase 1 (SphK1) and amplifies the intracellular concentration of sphingosine-1-phosphate (S1P) in breast cancer cells during stimulation of proliferation and survival. Specifically, Estrogen activates S1P receptors (S1PR) and induces growth factor receptor transactivation. SphK, S1P, and S1PR expression are causally associated with endocrine resistance and progression to advanced tumor stages in ER-positive breast cancers in vivo. Recently, the network of SphK/S1PR was shown to promote the development of ER-negative cancers and breast cancer stem cells, as well as stimulating angiogenesis. Novel findings confirm and broaden our knowledge about the cross-talk between sphingolipids and estrogen network in normal and malignant cells. Current S1PRs therapeutic inhibition was indicated as a promising chemotherapy approach in non-responsive and advanced malignancies. Considering that sphingolipid signaling has a prominent role in terminally differentiated cells, the impact should be considered when designing specific SphK/S1PR inhibitors. This study analyzes the dynamic of the transformation of sphingolipid axis during a transition from normal to pathological condition on the level of the whole organism. The sphingolipid-based mediation and facilitation of global effects of estrogen were critically accented as a bridging mechanism that should be explored in cancer prevention.

Advances of Sphingosine-1-phosphate in Angiogenesis

Sphingosine 1-Phosphate: A Potential Molecular Target for Ovarian Cancer Therapy?

Sphingosine Kinase 1/Sphingosine-1-phosphate (S1P)/S1P Receptor Axis is Involved in Ovarian Cancer Angiogenesis

The sphingosine kinase-1/sphingosine-1-phosphate axis in cancer: Potential target for anticancer therapy

Bioactive sphingolipids as emerging targets for signal transduction in cancer development

Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy.

Targeting Sphingosine-1-Phosphate Signaling in Breast Cancer

Recent advances in the role of sphingosine 1‐phosphate in cancer

Keep a Little Fire Burning—The Delicate Balance of Targeting Sphingosine-1-Phosphate in Cancer Immunity

Bioactive lipids lysophosphatidic acid and sphingosine 1-phosphate mediate breast cancer cell biological functions through distinct mechanisms

Expansion of Sphingosine Kinase and Sphingosine-1-Phosphate Receptor Function in Normal and Cancer Cells: From Membrane Restructuring to Mediation of Estrogen Signaling and Stem Cell Programming

Sphingosine-1-Phosphate in the Tumor Microenvironment: A Signaling Hub Regulating Cancer Hallmarks

Study on Effect of S1P/S1PR on Angiogenesis in SKOV3 Ovarian Cancer Cells

Sphingosine 1-phosphate and inflammation.

Sphingosine 1-phosphate receptor, a new therapeutic direction in different diseases

Role of Sphingosine-1-Phosphate Signaling Pathway in Pancreatic Diseases

Role of sphingosine-1-phosphate in the proliferation of human gastric carcinoma cell and human vascular endothelial cell

Advances in Tumor Angiogenesis Inhibitor

Pathogenic Role of the Sphingosine 1-Phosphate (S1P) Pathway in Common Gynecologic Disorders (GDs): A Possible Novel Therapeutic Target

The key role of sphingolipid metabolism in cancer: New therapeutic targets, diagnostic and prognostic values, and anti-tumor immunotherapy resistance

Progression of VEGF-targeted cancer therapy